Asiatic Laboratories (DHA:ASIATICLAB) Capex-to-Operating-Cash-Flow: 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ASIATICLAB Asiatic Laboratories Ltd DHA:ASIATICLAB
32 GF Score
Price BDT104.50
! 1 Warning Sign
View Full Analysis

What is Asiatic Laboratories Capex-to-Operating-Cash-Flow?

Asiatic Laboratories DHA:ASIATICLAB -1.42% 32 Capex-to-Operating-Cash-Flow is 0.00 as of . 20. GuruFocus rates DHA:ASIATICLAB with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 552 Drug Manufacturers companies, Asiatic Laboratories ranks worse than 181159.24% on this metric.

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Asiatic Laboratories's Capital Expenditure for the six months ended in . 20 was BDT0.00 Mil. Its Cash Flow from Operations for the six months ended in . 20 was BDT0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Asiatic Laboratories  (DHA:ASIATICLAB) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Asiatic Laboratories Capex-to-Operating-Cash-Flow Related Terms


Asiatic Laboratories Capex-to-Operating-Cash-Flow Historical Data

* Premium members only.

The historical data trend for Asiatic Laboratories's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Asiatic Laboratories Capex-to-Operating-Cash-Flow Chart

Asiatic Laboratories Annual Data
Trend
Capex-to-Operating-Cash-Flow

Asiatic Laboratories Semi-Annual Data
Capex-to-Operating-Cash-Flow

DHA:ASIATICLAB vs ZTS, UTHR, VTRS: Capex-to-Operating-Cash-Flow Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Asiatic Laboratories's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Asiatic Laboratories Capex-to-Operating-Cash-Flow vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Asiatic Laboratories's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Asiatic Laboratories's Capex-to-Operating-Cash-Flow falls into.


DHA:ASIATICLAB
32GF Score
Asiatic Laboratories Ltd DHA:ASIATICLAB
Capex-to-Operating-Cash-Flow is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Asiatic Laboratories Capex-to-Operating-Cash-Flow Calculation

Asiatic Laboratories's Capex-to-Operating-Cash-Flow for the fiscal year that ended in . 20 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- () /
=N/A

Asiatic Laboratories's Capex-to-Operating-Cash-Flow for the quarter that ended in . 20 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- () /
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Capex-to-Operating-Cash-Flow of 0.00 mean?
Asiatic Laboratories (DHA:ASIATICLAB) has a Capex-to-Operating-Cash-Flow of 0.00 as of . 20. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Asiatic Laboratories and its competitors. According to the industry distribution chart, Asiatic Laboratories ranks #999999 out of 552 companies in the Drug Manufacturers industry.
Is Asiatic Laboratories' Capex-to-Operating-Cash-Flow too high?
Asiatic Laboratories' current Capex-to-Operating-Cash-Flow is 0.00. Based on the distribution chart, Asiatic Laboratories ranks #999999 out of 552 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Asiatic Laboratories has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Asiatic Laboratories' Capex-to-Operating-Cash-Flow compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Asiatic Laboratories ranks #999999 out of 552 companies for Capex-to-Operating-Cash-Flow. This places Asiatic Laboratories in the lower half of its industry. The industry median Capex-to-Operating-Cash-Flow is 0.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Drug Manufacturers company?
The median Capex-to-Operating-Cash-Flow among Drug Manufacturers companies is 0.36, based on 552 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Asiatic Laboratories and its competitors. For the Drug Manufacturers industry, the median Capex-to-Operating-Cash-Flow is 0.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asiatic Laboratories's current Capex-to-Operating-Cash-Flow is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asiatic Laboratories stock overvalued right now?
Asiatic Laboratories (DHA:ASIATICLAB) has a current Capex-to-Operating-Cash-Flow of 0.00. The current Capex-to-Operating-Cash-Flow is 0.00. Asiatic Laboratories' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For Asiatic Laboratories (DHA:ASIATICLAB), the current Capex-to-Operating-Cash-Flow is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Asiatic Laboratories Business Description

Address Siddeshwari Circular Road, 42-43, Treasure Island (5 th Floor) Shantinagar, Dhaka, BGD, 1217
Asiatic Laboratories Ltd is engaged in manufacturing and marketing of a wide range of the rapeutical medicines pharmaceutical products in the categories of Biological, Non-Biological & Sterile Pharmaceutical dosage. It has 80 generic molecules comprising therapeutic classes like antibiotics, antihistamines, bronchodilators, vitamins-minerals, antiulcerants, laxatives, gastroprokinetics, antihematinic, anthelmentics, CNS drugs, respiratory drugs, NSAIDs, dermatological preparations and sterile ophthalmic preparations.
32GF Score

Get the complete analysis for DHA:ASIATICLAB

Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT104.50
Price